Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Respiratory virus season is arriving, once again, and the La Plata County Public Health Department is urging residents to ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
We get the latest guidance on how to survive the viral season.
RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...
RSV is the most harmful respiratory illness for young infants, says Dr. Jeffrey Pernica, a professor in the Department of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback